Tempest Therapeutics, Inc.
TPST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $389 | $0 | $0 | $0 |
| Gross Profit | -$389 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $28,476 | $17,498 | $22,527 | $17,166 |
| G&A Expenses | $13,550 | $11,659 | $12,113 | $9,820 |
| SG&A Expenses | $13,550 | $11,659 | $12,113 | $9,820 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$389 | $0 | $0 | $0 |
| Operating Expenses | $41,637 | $29,157 | $34,640 | $26,986 |
| Operating Income | -$42,026 | -$29,157 | -$34,640 | -$26,986 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $183 | -$334 | -$1,069 | -$1,316 |
| Pre-Tax Income | -$41,843 | -$29,491 | -$35,709 | -$28,302 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$41,843 | -$29,491 | -$35,709 | -$28,302 |
| % Margin | – | – | – | – |
| EPS | -1.5 | -1.91 | -3.18 | -7.8 |
| % Growth | 21.5% | 39.9% | 59.2% | – |
| EPS Diluted | -1.5 | -1.91 | -3.18 | -7.8 |
| Weighted Avg Shares Out | 27,902 | 15,416 | 888 | 291 |
| Weighted Avg Shares Out Dil | 27,902 | 15,416 | 888 | 292 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,499 | $1,115 | $549 | $1 |
| Interest Expense | $1,316 | $1,449 | $1,618 | $1,282 |
| Depreciation & Amortization | $389 | $381 | $638 | $374 |
| EBITDA | -$40,138 | -$27,661 | -$33,453 | -$26,646 |
| % Margin | – | – | – | – |